Ocrelizumab is in the medical press once again, before trial results in PPMS and RRMS are presented at ECTRIMS. But absent from all of the glowing medical news is the history of this drug, which was discontinued in phase III testing in Lupus and RA patients, after numerous serious infections and 11 deaths. No mention in the press. Nothing. I believe pwMS deserve to know all of the facts. This may be a helpful drug for those w/ PPMS---but to not disclose deaths is a disservice. Joan